LC-MB12 NEW
| Price | $157 | $345 | $550 |
| Package | 1mg | 5mg | 10mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2025-06-17 |
Product Details
| Product Name: LC-MB12 | CAS No.: 2828438-38-4 |
| Purity: 99.16% | Supply Ability: 10g |
| Release date: 2025/06/17 |
Product Introduction
Bioactivity
| Name | LC-MB12 |
| Description | LC-MB12 is an orally active, selective and potent PROTAC FGFR2 complex that degrades FGFR2.LC-MB12 has antiproliferative and antitumor activity.LC-MB12 is used in the study of gastric cancer because of its inhibition of FGFR2 signaling.LC-MB12 has been shown to have antiproliferative and antitumor activity.LC-MB12 has been shown to have antiproliferative and antitumor activity. |
| In vitro | 0.5-10000 nM LC-MB12, FGFR2 was degraded in KATO III in a time-dependent manner over 3-12 hours, DC50=11.8 nM. [1] 100 nM LC-MB12 treatment for 6 hours resulted in 77% degradation of FGFR2 in KATO III and 43% degradation in NCI-H1581. [1] 1-10000 nM LC-MB12 treatment for 72 h significantly inhibited the growth of KATO III, SNU-16, and NCI-H716 with IC50=29.1 nM (KATO III), IC50=3.7 nM (SNU-16), and IC50=3.2 nM (NCI-H716), respectively, and induced KATO III G0 /G1 phase block. [1] |
| In vivo | Oral administration of 20 mg/kg LC-MB12 was rapidly absorbed in mice (Cmax: 2.6 h) with oral bioavailability (F: 13%). Oral administration for 30 days was well tolerated and showed no significant hepatotoxicity or nephrotoxicity in mice. [1] 20 mg/kg/day LC-MB12 administered orally for 15 days inhibited tumor growth by 63.1% in the SNU-16 nude mouse xenograft model. [1] |
| Storage | keep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 120 mg/mL(133.37 mM), Sonication is recommended. |
| Keywords | PROTAC | FGFR2 |
| Inhibitors Related | Amlexanox | Nintedanib | ARV-471 | Ferulic Acid | Ponatinib | Nintedanib esylate | Pemigatinib | Formononetin | Lenvatinib mesylate | Erdafitinib | Lenvatinib | Pazopanib |
| Related Compound Libraries | Bioactive Compound Library | Bioactive Compounds Library Max |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $0.00/100mg |
VIP2Y
|
Xian confluore Biological Technology Co., Ltd.
|
2024-03-30 | |
| $148.00/100mg |
VIP3Y
|
TargetMol Chemicals Inc.
|
2025-06-03 | |
| $2180.00/50mg |
VIP1Y
|
TargetMol Chemicals Inc.
|
2025-05-01 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY